Trial Profile

Phase IV Study of Respiratory Syncytial Virus Monoclonal Antibody Therapy in High-risk Infants and Toddlers

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Mar 2020 Results of subgroup analysis of three subgroups: immunocompromised group: n=214, complex medical disorders group: n=4283 and standard indications group: n=20506, assessing respiratory illness hospitalization and RSV-related hospitalization hazard ratios were published in the Pediatric Infectious Disease Journal
30 Nov 2018 Results (n=21,107) assessing risk of respiratory illness- and RSV-related hospitalizations (RIH and RSVH, respectively) among infants prophylaxed for CDH, standard indications (SI), and those without increased risk (NR), published in the Clinical Infectious Diseases.
04 May 2018 Results (n=23,228) published in the European Journal of Clinical Microbiology and Infectious Diseases.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com